CEPI partners with Gennova Biopharmaceuticals for saRNA vaccine development against 'Disease X'
CEPI emphasizes the increasing risk of 'Disease X' outbreaks worldwide
CEPI emphasizes the increasing risk of 'Disease X' outbreaks worldwide
CEPI provides $3.6 million to optimize self-amplifying mRNA (saRNA) platform technology
CEPI provides $3.6 million to optimize self-amplifying mRNA (saRNA) platform technology
Vaccine candidate against rabies virus to be developed for preclinical studies.
Vaccine candidate against rabies virus to be developed for preclinical studies.
Advances in RNA-vaccine tech critical for future pandemic responses.
Advances in RNA-vaccine tech critical for future pandemic responses.
SaRNA vaccines use genetic info to trigger host cells' self-amplification.
SaRNA vaccines use genetic info to trigger host cells' self-amplification.
Gennova's unique CLNE delivery system for saRNA vaccines.
Gennova's unique CLNE delivery system for saRNA vaccines.
CEPI's funding aims for vaccine democratisation and equitable access.
CEPI's funding aims for vaccine democratisation and equitable access.
Collaboration between CEPI and Gennova to enhance saRNA technology for global health.
Collaboration between CEPI and Gennova to enhance saRNA technology for global health.